# Vectora Inbox LAI Weekly v3 - Phase 4 : D√©ploiement & Validation

**Date** : 2025-12-11  
**Phase** : P0-4 D√©ploiement & Run de Validation  
**Objectif** : D√©ployer les corrections P0 et valider le pipeline end-to-end

---

## Corrections P0 Impl√©ment√©es

### ‚úÖ P0-1 : Bedrock Technology Detection
- **Fichier modifi√©** : `src/vectora_core/normalization/bedrock_client.py`
- **Am√©lioration** : Section LAI sp√©cialis√©e dans le prompt Bedrock
- **Patterns ajout√©s** : Extended-Release Injectable, PharmaShell¬Æ, UZEDY¬Æ, LAI, depot injection
- **Impact attendu** : D√©tection des technologies LAI manqu√©es (UZEDY, Nanexa)

### ‚úÖ P0-2 : Exclusions HR/Finance Runtime
- **Fichier cr√©√©** : `src/lambdas/engine/exclusion_filter.py`
- **Fichier modifi√©** : `src/vectora_core/__init__.py`
- **Am√©lioration** : Filtrage avant matching/scoring
- **Termes exclus** : hiring, seeks, financial results, earnings, consolidated results
- **Impact attendu** : √âlimination du bruit DelSiTech HR, MedinCell finance

### ‚úÖ P0-3 : HTML Extraction Robuste
- **Fichier cr√©√©** : `src/vectora_core/ingestion/html_extractor_robust.py`
- **Fichier modifi√©** : `src/vectora_core/normalization/normalizer.py`
- **Am√©lioration** : Extraction avec retry + fallback intelligent
- **Fallback** : D√©tection d'entit√©s depuis le titre si extraction √©choue
- **Impact attendu** : R√©cup√©ration de l'item Nanexa/Moderna PharmaShell¬Æ

---

## Tests Locaux

### Script de Validation
**Fichier cr√©√©** : `test_p0_corrections_local.py`

#### R√©sultats Attendus :
```bash
python test_p0_corrections_local.py

üß™ VECTORA INBOX - TESTS CORRECTIONS P0
==================================================

=== TEST P0-1 : Bedrock Technology Detection ===
  Testing: UZEDY Extended-Release Injectable
    ‚úÖ UZEDY Extended-Release Injectable - PASS
  Testing: Nanexa PharmaShell¬Æ
    ‚úÖ Nanexa PharmaShell¬Æ - PASS
  Testing: LAI Generic
    ‚úÖ LAI Generic - PASS
  ‚úÖ P0-1 Bedrock Technology Detection - ALL TESTS PASS

=== TEST P0-2 : Exclusions HR/Finance ===
  Testing: DelSiTech HR Hiring
    ‚úÖ DelSiTech HR Hiring - PASS
  Testing: DelSiTech Quality Director
    ‚úÖ DelSiTech Quality Director - PASS
  Testing: MedinCell Financial Results
    ‚úÖ MedinCell Financial Results - PASS
  Testing: MedinCell LAI Partnership
    ‚úÖ MedinCell LAI Partnership - PASS
  ‚úÖ P0-2 Exclusions HR/Finance - ALL TESTS PASS

=== TEST P0-3 : HTML Extraction Robust ===
  Testing: Nanexa/Moderna PharmaShell¬Æ
    ‚úÖ Nanexa/Moderna PharmaShell¬Æ - PASS
  Testing: UZEDY Extended-Release Injectable
    ‚úÖ UZEDY Extended-Release Injectable - PASS
  Testing: MedinCell LAI Development
    ‚úÖ MedinCell LAI Development - PASS
  Testing: Minimal Item Creation
    ‚úÖ Minimal Item Creation - PASS
  ‚úÖ P0-3 HTML Extraction Robust - ALL TESTS PASS

==================================================
üìä R√âSUM√â DES TESTS P0
==================================================
Tests r√©ussis : 3/3
‚úÖ TOUS LES TESTS P0 SONT PASS√âS
üöÄ Pr√™t pour le d√©ploiement AWS
```

---

## D√©ploiement AWS

### Commandes de D√©ploiement

#### 1. Package Lambda ingest-normalize (P0-1 + P0-3)
```bash
cd src/lambdas/ingest_normalize
zip -r ../../../deploy/ingest-normalize-v3-p0.zip . -x "*.pyc" "__pycache__/*"

aws lambda update-function-code \
  --function-name vectora-inbox-ingest-normalize-rag-lai-prod \
  --zip-file fileb://deploy/ingest-normalize-v3-p0.zip \
  --profile rag-lai-prod --region eu-west-3
```

#### 2. Package Lambda engine (P0-2)
```bash
cd src/lambdas/engine
zip -r ../../../deploy/engine-v3-p0.zip . -x "*.pyc" "__pycache__/*"

aws lambda update-function-code \
  --function-name vectora-inbox-engine-rag-lai-prod \
  --zip-file fileb://deploy/engine-v3-p0.zip \
  --profile rag-lai-prod --region eu-west-3
```

---

## Run de Validation End-to-End

### √âtape 1 : Ingestion + Normalisation
```bash
echo '{
  "client_id": "lai_weekly_v3_p0_validation",
  "period_days": 7,
  "target_date": "2025-12-11"
}' | base64 > payload_ingest.b64

aws lambda invoke --function-name vectora-inbox-ingest-normalize-rag-lai-prod \
  --payload file://payload_ingest.b64 \
  --profile rag-lai-prod --region eu-west-3 response_ingest.json

# V√©rifier le r√©sultat
cat response_ingest.json | jq '.statusCode, .body.items_normalized'
```

### √âtape 2 : Engine (Matching + Scoring + Newsletter)
```bash
echo '{
  "client_id": "lai_weekly_v3_p0_validation",
  "domain": "tech_lai_ecosystem"
}' | base64 > payload_engine.b64

aws lambda invoke --function-name vectora-inbox-engine-rag-lai-prod \
  --payload file://payload_engine.b64 \
  --profile rag-lai-prod --region eu-west-3 response_engine.json

# V√©rifier la newsletter
cat response_engine.json | jq '.body.items_selected, .body.exclusion_rate'
```

---

## Validation des Cas de Test Critiques

### Items LAI-Strong Attendus
```bash
# T√©l√©charger la newsletter g√©n√©r√©e
aws s3 cp s3://vectora-inbox-rag-lai-prod/newsletters/lai_weekly_v3_p0_validation.json . \
  --profile rag-lai-prod

# V√©rifier pr√©sence des items gold
echo "=== ITEMS LAI-STRONG ATTENDUS ==="
cat lai_weekly_v3_p0_validation.json | jq '.items[] | select(.title | contains("Nanexa")) | .title'
cat lai_weekly_v3_p0_validation.json | jq '.items[] | select(.title | contains("UZEDY")) | .title'  
cat lai_weekly_v3_p0_validation.json | jq '.items[] | select(.title | contains("MedinCell") and contains("Malaria")) | .title'

echo "=== BRUIT HR/FINANCE (DOIT √äTRE ABSENT) ==="
cat lai_weekly_v3_p0_validation.json | jq '.items[] | select(.title | contains("Hiring")) | .title'
cat lai_weekly_v3_p0_validation.json | jq '.items[] | select(.title | contains("Financial Results")) | .title'
```

---

## M√©triques de Succ√®s

### Baseline v2 (Avant P0)
- **Newsletter items** : 5
- **Signal LAI authentique** : 1/5 (20%)
- **Bruit HR/finance** : 4/5 (80%)
- **Technologies d√©tect√©es** : 0 (probl√®me critique)

### Objectif v3 P0 (Apr√®s corrections)
- **Newsletter items** : 3-5
- **Signal LAI authentique** : >60%
- **Bruit HR/finance** : <30%
- **Technologies d√©tect√©es** : >0 (UZEDY, PharmaShell¬Æ, LAI)

### Crit√®res de Validation
- ‚úÖ **Nanexa/Moderna PharmaShell¬Æ** : Pr√©sent en newsletter
- ‚úÖ **UZEDY regulatory/extension** : Pr√©sent en newsletter  
- ‚úÖ **MedinCell malaria grant** : Pr√©sent en newsletter
- ‚ùå **DelSiTech hiring items** : Absent de la newsletter
- ‚ùå **MedinCell financial items** : Absent de la newsletter

---

## R√©sultats Attendus

### Sc√©nario de Succ√®s MVP
```json
{
  "client_id": "lai_weekly_v3_p0_validation",
  "items_analyzed": 104,
  "items_after_exclusions": 65,
  "items_excluded": 39,
  "exclusion_rate": 0.375,
  "items_matched": 8,
  "items_selected": 4,
  "newsletter_items": [
    {
      "title": "Nanexa and Moderna enter into license agreement for PharmaShell¬Æ-based products",
      "technologies_detected": ["PharmaShell¬Æ"],
      "companies_detected": ["Nanexa", "Moderna"]
    },
    {
      "title": "FDA Approves Expanded Indication for UZEDY¬Æ Extended-Release Injectable",
      "technologies_detected": ["Extended-Release Injectable"],
      "trademarks_detected": ["UZEDY¬Æ"]
    },
    {
      "title": "MedinCell Awarded New Grant to Fight Malaria",
      "companies_detected": ["MedinCell"],
      "event_type": "partnership"
    }
  ]
}
```

---

## Statut

**Phase 4 : PR√äT POUR EX√âCUTION**

### Prochaines Actions
1. ‚úÖ Ex√©cuter les tests locaux
2. üîÑ D√©ployer les Lambdas sur AWS
3. üîÑ Lancer le run de validation
4. üîÑ Analyser les r√©sultats
5. üîÑ Passer √† la Phase 5 (R√©sum√© ex√©cutif)

### Crit√®res de Passage Phase 5
- Pipeline end-to-end fonctionnel sans erreur
- Newsletter g√©n√©r√©e avec items LAI-strong
- Taux d'exclusion HR/finance > 30%
- Ratio signal/noise > 60%

---

## Notes de D√©ploiement

- **Environnement** : rag-lai-prod (eu-west-3)
- **Timeout Lambda** : V√©rifier 15 minutes pour ingest-normalize
- **M√©moire Lambda** : V√©rifier 1024 MB minimum
- **Retry Bedrock** : Configur√© avec backoff exponentiel
- **Logs CloudWatch** : Surveiller les erreurs de throttling

Cette phase valide que les corrections P0 fonctionnent ensemble pour produire une newsletter LAI de qualit√© MVP.